Neoadjuvant immunotherapy for resectable primary liver cancer
(Review)
- Authors:
- Qingsong Deng
- Minglian He
- Leida Zhang
- Yuzhang Wu
-
Affiliations: Institute of Immunology, Third Military Medical University, Army Medical University, Chongqing 400038, P.R. China, Army Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Army Medical University, Chongqing 400038, P.R. China - Published online on: July 23, 2025 https://doi.org/10.3892/ol.2025.15204
- Article Number: 458
-
Copyright : © Deng et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Abstract
 |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.PubMed/NCBI | |
|
Reveron-Thornton RF, Teng MLP, Lee EY, Tran A, Vajanaphanich S, Tan EX, Nerurkar SN, Ng RX, Teh R, Tripathy DP, et al: Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies. Hepatol Commun. 6:1813–1826. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 17:557–588. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, et al: Changing cancer survival in China during 2003-15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 6:e555–e567. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Wen N, Cai Y, Li F, Ye H, Tang W, Song P and Cheng N: The clinical management of hepatocellular carcinoma worldwide: A concise review and comparison of current guidelines: 2022 update. Biosci Trends. 16:20–30. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Glantzounis GK, Karampa A, Peristeri DV, Pappas-Gogos G, Tepelenis K, Tzimas P and Cyrochristos DJ: Recent advances in the surgical management of hepatocellular carcinoma. Ann Gastroenterol. 34:453–465. 2021.PubMed/NCBI | |
|
Ryon EL, Kronenfeld JP, Lee RM, Yopp A, Wang A, Lee AY, Luu S, Hsu C, Silberfein E, Russell MC, et al: Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States safety net and academic center collaborative analysis. J Surg Oncol. 123:407–415. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu P, Liao W, Zhang WG, Chen L, Shu C, Zhang ZW, Huang ZY, Chen YF, Lau WY, Zhang BX and Chen XP: A prospective study using propensity score matching to compare Long-term survival outcomes after robotic-assisted, laparoscopic, or open liver resection for patients with BCLC stage 0-A hepatocellular carcinoma. Ann Surg. 277:e103–e111. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK and Are C: A review and update of treatment options and controversies in the management of hepatocellular carcinoma. Ann Surg. 263:1112–1125. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Tabrizian P, Jibara G, Shrager B, Schwartz M and Roayaie S: Recurrence of hepatocellular cancer after resection: Patterns, treatments, and prognosis. Ann Surg. 261:947–955. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Erstad DJ and Tanabe KK: Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma. Ann Surg Oncol. 26:1474–1493. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, Labow D, Llovet JM, Schwartz M and Mazzaferro V: Resection of hepatocellular cancer </=2 cm: Results from two Western centers. Hepatology. 57:1426–1435. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Feng YX, Wang T, Deng YZ, Yang P, Li JJ, Guan DX, Yao F, Zhu YQ, Qin Y, Wang H, et al: Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology. 53:483–492. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Wang SN, Chuang SC and Lee KT: Efficacy of sorafenib as adjuvant therapy to prevent early recurrence of hepatocellular carcinoma after curative surgery: A pilot study. Hepatol Res. 44:523–531. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Zhao G, Wei K, Zhang Q, Ma W, Song T, Wu Q, Zhang T, Kong D and Li Q: Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: A single-center experience. Biosci Trends. 8:333–338. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, et al: Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. J Hematol Oncol. 9:202016. View Article : Google Scholar : PubMed/NCBI | |
|
Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, et al: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16:1344–1354. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 389:2492–2502. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, et al: Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 randomized clinical trial. JAMA Oncol. 6:e2045642020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, et al: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lygidakis NJ, Ziras N and Parissis J: Resection versus resection combined with adjuvant pre- and post-operative chemotherapy-immunotherapy for metastatic colorectal liver cancer. A new look at an old problem. Hepatogastroenterology. 42:155–161. 1995.PubMed/NCBI | |
|
Lygidakis NJ, Stringaris K, Kokinis K, Lyberopoulos K and Raptis S: Locoregional chemotherapy versus locoregional combined immuno-chemotherapy for patients with advanced metastatic liver disease of colorectal origin: A prospective randomized study. Hepatogastroenterology. 43:212–220. 1996.PubMed/NCBI | |
|
Lygidakis NJ, Sgourakis G, Vlachos L, Raptis S, Safioleas M, Boura P, Kountouras J and Alamani M: Metastatic liver disease of colorectal origin: the value of locoregional immunochemotherapy combined with systemic chemotherapy following liver resection. Results of a prospective randomized study. Hepatogastroenterology. 48:1685–1691. 2001.PubMed/NCBI | |
|
Gardini A, Ercolani G, Riccobon A, Ravaioli M, Ridolfi L, Flamini E, Ridolfi R, Grazi GL, Cavallari A and Amadori D: Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol. 87:46–52. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Chiang J, Chen PC, Pham J, Nguyen CQ, Kaur K, Raman SS and Jewett A: Characterizing hepatocellular carcinoma stem markers and their corresponding susceptibility to NK-cell based immunotherapy. Front Immunol. 14:12846692023. View Article : Google Scholar : PubMed/NCBI | |
|
Hou J, Zhang H, Sun B and Karin M: The immunobiology of hepatocellular carcinoma in humans and mice: Basic concepts and therapeutic implications. J Hepatol. 72:167–182. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Tong S, Hu B, Wan T, Tang H, Zhao F, Jiao T, Li J, Zhang Z, Cai J, et al: Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: A single-arm, phase II trial. J Immunother Cancer. 11:e0073662023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen DS and Hurwitz H: Combinations of bevacizumab with cancer immunotherapy. Cancer J. 24:193–204. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, et al: Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 382:1894–1905. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Finn RS, Ryoo B, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, et al: Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J Clin Oncol. 38:193–202. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao M, Chen S, Li C, Du Y and Li P: Neoadjuvant immune checkpoint inhibitors for resectable hepatocellular carcinoma: A systematic review and meta-analysis. Cancers (Basel). 15:6002023. View Article : Google Scholar : PubMed/NCBI | |
|
Kelley RK, Abou-Alfa G, Bendell JC, Kim TY, Borad MJ, Yong WP, Morse M, Kang YK, Rebelatto M, Makowsky M, et al: Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J Clin Oncol. 35:40732017. View Article : Google Scholar | |
|
Stein S, Pishvaian M, Lee MS, Lee KH, Hernandez S, Kwan A, Liu B, Grossman W, Iizuka K and Ryoo BY: Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC). J Clin Oncol. 36:40742018. View Article : Google Scholar | |
|
Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, et al: A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 59:81–88. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kaseb AO, Hasanov E, Cao HST, Xiao L, Vauthey JN, Lee SS, Yavuz BG, Mohamed YI, Qayyum A, et al: Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 7:208–218. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang WQ, Zhang Q, Tan L, Guan ZF, Tian F, Tang HT, He K and Chen WQ: Postoperative adjuvant immunotherapy for high-risk hepatocellular carcinoma patients. Front Oncol. 13:12899162023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Hu S, Liu Z, Sun Y, Wu J, Shen S and Peng Z: Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy. Hepatol Int. 17:406–416. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, et al: Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): A randomised, open-label, multicentre, phase 3 trial. Lancet. 402:1835–1847. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Xu X, Wang MD, Xu JH, Fan ZQ, Diao YK, Chen Z, Jia HD, Liu FB, Zeng YY, Wang XM, et al: Adjuvant immunotherapy improves recurrence-free and overall survival following surgical resection for intermediate/advanced hepatocellular carcinoma a multicenter propensity matching analysis. Front Immunol. 14:13222332024. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Wu PS, Liang XM, Chen K, Zhang GL, Su QB, Huo RR, Xie RW, Huang S, Ma L and Zhong JH: Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): A prospective, multicentric cohort study. J Gastroenterol. 58:1043–1054. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Qin YY, Shi J, Guo WX, Lu CD, Zheng YX, et al: Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: A randomized, controlled, phase 2 trial. Nat Med. 30:708–715. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Zimmer L, Livingstone E, Hassel JC, Fluck M, Eigentler T, Loquai C, Haferkamp S, Gutzmer R, Meier F, Mohr P, et al: Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 395:1558–1568. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Wakelee HA, Altorki N, Zhou C, Csőszi T, Vynnychenko IO, Goloborodko O, Luft A, Akopov A, Martinez-Marti A, Kenmotsu H, et al: IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. 39 (15_suppl):S85002021. View Article : Google Scholar | |
|
Tang F, Tie Y, Tu C and Wei X: Surgical trauma-induced immunosuppression in cancer: Recent advances and the potential therapies. Clin Transl Med. 10:199–223. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Jia R, Zhou M, Tuttle CSL and Maier AB: Immune capacity determines outcome following surgery or trauma: A systematic review and meta-analysis. Eur J Trauma Emerg Surg. 46:979–991. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Bakos O, Lawson C, Rouleau S and Tai LH: Combining surgery and immunotherapy: Turning an immunosuppressive effect into a therapeutic opportunity. J Immunother Cancer. 6:862018. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng X, Zhang H, Hamad A, Huang H and Tsung A: Surgery-mediated tumor-promoting effects on the immune microenvironment. Semin Cancer Biol. 86:408–419. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, et al: Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 24:1655–1661. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, et al: Successful Anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-gamma and IL-12. Immunity. 49:1148–1161. e72018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu J, Blake SJ, Yong MC, Harjunpää H, Ngiow SF, Takeda K, Young A, O'Donnell JS, Allen S, Smyth MJ and Teng MW: Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6:1382–1399. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, et al: Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 378:1976–1986. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Xia Y, Tang W, Qian X, Li X, Cheng F, Wang K, Zhang F, Zhang C, Li D, Song J, et al: Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: A single-arm, open label, phase II clinical trial. J Immunother Cancer. 10:e0046562022. View Article : Google Scholar : PubMed/NCBI | |
|
Qiao ZY, Zhang ZJ, Lv ZC, Tong H, Xi ZF, Wu HX, Chen XS, Xia L, Feng H, Zhang JJ and Xia Q: Neoadjuvant programmed cell death 1 (PD-1) inhibitor treatment in patients with hepatocellular carcinoma before liver transplant: A cohort study and literature review. Front Immunol. 12:6534372021. View Article : Google Scholar : PubMed/NCBI | |
|
Marron TU, Fiel MI, Hamon P, Fiaschi N, Kim E, Ward SC, Zhao Z, Kim J, Kennedy P, Gunasekaran G, et al: Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: A single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 7:219–229. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Pinato DJ, Cortellini A, Sukumaran A, Cole T, Pai M, Habib N, Spalding D, Sodergren MH, Martinez M, Dhillon T, et al: PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma. BMC Cancer. 21:3012021. View Article : Google Scholar : PubMed/NCBI | |
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al: The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 29:n712021. View Article : Google Scholar : PubMed/NCBI | |
|
Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebbé C, Delord JP, Dunn LA, Shinohara MM, Kulikauskas R, et al: Neoadjuvant nivolumab for patients with resectable merkel cell carcinoma in the checkmate 358 trial. J Clin Oncol. 38:2476–2487. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, et al: Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: Survival, genomic and immunologic analyses from the phase 2 PrE0505 trial. Nat Med. 27:1910–1920. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Schmid P, Cortes JA, Dent R, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, Park YH, Hui R, et al: VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab+ chemotherapy vs. placebo+chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC. Ann Oncol. 32:1198–1200. 2021. View Article : Google Scholar | |
|
Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, Felip E, Broderick S, Brahmer J, Swanson SJ, et al: Abstract CT003: Nivolumab (NIVO)+ platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial. Cancer Res. 81 (13_Suppl):CT0032021. View Article : Google Scholar | |
|
Ho WJ, Zhu Q, Durham J, Popovic A, Xavier S, Leatherman J, Mohan A, Mo G, Zhang S, Gross N, et al: Neoadjuvant cabozantinib and nivolumab converts locally advanced HCC into resectable disease with enhanced antitumor immunity. Nat Cancer. 2:891–903. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cascone T, William WN Jr, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, et al: Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat Med. 27:504–514. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, et al: A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 25:454–461. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Uppaluri R, Campbell KM, Egloff AM, Zolkind P, Skidmore ZL, Nussenbaum B, Paniello RC, Rich JT, Jackson R, Pipkorn P, et al: Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, phase II Trial. Clin Cancer Res. 26:5140–5152. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Gatteschi L, Iannopollo M and Gonfiotti A: Neoadjuvant immunotherapy in resectable non-small cell lung cancer. A narrative review. Life (Basel). 11:10362021.PubMed/NCBI | |
|
Hou S, Pan Z, Hao X, Hang Q and Ding Y: Recent progress in the neoadjuvant treatment strategy for locally advanced esophageal cancer. Cancers (Basel). 13:51622021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang ZY and Chen YF: Long-term outcome of resection of large hepatocellular carcinoma. Br J Surg. 93:600–606. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Sotiropoulos GC, Molmenti E, Lösch C, Beckebaum S, Broelsch CE and Lang H: Meta-analysis of tumor recurrence after liver transplantation for hepatocellular carcinoma based on 1,198 cases. Eur J Med Res. 12:527–534. 2007.PubMed/NCBI | |
|
Rich NE, Parikh ND and Singal AG: Hepatocellular carcinoma and liver transplantation: Changing patterns and practices. Curr Treat Options Gastroenterol. 15:296–304. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kayashima H, Toshima T, Okano S, Taketomi A, Harada N, Yamashita Y, Tomita Y, Shirabe K and Maehara Y: Intratumoral neoadjuvant immunotherapy using IL-12 and dendritic cells is an effective strategy to control recurrence of murine hepatocellular carcinoma in immunosuppressed mice. J Immunol. 185:698–708. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Schwacha-Eipper B, Minciuna I, Banz V and Dufour JF: Immunotherapy as a downstaging therapy for liver transplantation. Hepatology. 72:1488–1490. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Abdelrahim M, Esmail A, Umoru G, Westhart K, Abudayyeh A, Saharia A and Ghobrial RM: Immunotherapy as a neoadjuvant therapy for a patient with hepatocellular carcinoma in the pretransplant setting: A case report. Curr Oncol. 29:4267–4273. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Finn RS, Ryoo B, Merle P, Kudo M, Bouattour M, Lim HY, Breder VV, Edeline J, Chao Y, Ogasawara S, et al: Results of KEYNOTE-240: Phase 3 study of pembrolizumab (pembro) vs best supportive care (BSC) for second lien therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 37:40042019. View Article : Google Scholar | |
|
Gassmann D, Weiler S, Mertens JC, Reiner CS, Vrugt B, Nägeli M, Mangana J, Müllhaupt B, Jenni F and Misselwitz B: Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transplant Direct. 4:e3762018. View Article : Google Scholar : PubMed/NCBI | |
|
Ho CM, Chen HL, Hu RH and Lee PH: Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: A review from a transplant oncology perspective. Ther Adv Med Oncol. 11:17588359198434632019. View Article : Google Scholar : PubMed/NCBI | |
|
Tabrizian P, Holzner M, Ajmera V, Kim AK, Zhou K, Schnickel GT, Torosian K, Hoteit M, Marino R, Li M, et al: Intention-to-treat outcomes of patients with hepatocellular carcinoma receiving immunotherapy before liver transplant: The multicenter VITALITY study. J Hepatol. 82:512–522. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Abdelrahim M, Esmail A, Divatia MK, Xu J, Kodali S, Victor DW, Brombosz E, Connor AA, Saharia A, Elaileh A, et al: Utilization of immunotherapy as a neoadjuvant therapy for liver transplant recipients with hepatocellular carcinoma. J Clin Med. 13:30682024. View Article : Google Scholar : PubMed/NCBI | |
|
Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, De Carlis L, Colledan M, Salizzoni M, Romagnoli R, Antonelli B, et al: Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): A randomised, controlled, phase 2b/3 trial. Lancet Oncol. 21:947–956. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X, Zhu Q, Cai J, Yang Z, Gu G, Pang L, Su M, Zhang F, Lin H, Wu W, et al: Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation. Cancer Immunol Immunother. 74:182024. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Y, Yan Y, Liu D, Tang J, Zhang H, Liu X, Wu Y and Cui X: Risk of transplant rejection associated with ICIs prior to liver transplantation in HCC: A multicenter retrospective study. Int Immunopharmacol. 143:1134002024. View Article : Google Scholar : PubMed/NCBI | |
|
Rezaee-Zavareh MS, Yeo YH, Wang T, Guo Z, Tabrizian P, Ward SC, Barakat F, Hassanein TI, Dave S, Ajmera V, et al: Impact of pre-transplant immune checkpoint inhibitor use on post-transplant outcomes in HCC: A systematic review and individual patient data meta-analysis. J Hepatol. 82:107–119. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Tabrizian P, Marino R, Bhoori S, Zeitlhoefler M, Mehta N, Banz V, Gruttadauria S, Iavarone M, Mazzarelli C, Simonotti N, et al: Neoadjuvant atezolizumab plus bevacizumab prior liver transplantation for hepatocellular carcinoma. JHEP Rep. 7:1012462025. View Article : Google Scholar : PubMed/NCBI | |
|
Kuo FC, Chen CY, Lin NC, Liu C, Hsia CY and Loong CC: Optimizing the safe washout period for liver transplantation following immune checkpoint inhibitors with atezolizumab, nivolumab, or pembrolizumab. Transplant Proc. 55:878–883. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar V, Shinagare AB, Rennke HG, Ghai S, Lorch JH, Ott PA and Rahma OE: The safety and efficacy of checkpoint inhibitors in transplant recipients: A case series and systematic review of literature. Oncologist. 25:505–514. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Toso C, Meeberg G, Hernandez-Alejandro R, Dufour JF, Marotta P, Majno P and Kneteman N: Total tumor volume and alpha-fetoprotein for selection of transplant candidates with hepatocellular carcinoma: A prospective validation. Hepatology. 62:158–165. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Laschtowitz A, Roderburg C, Tacke F and Mohr R: Preoperative immunotherapy in hepatocellular carcinoma: Current state of the art. J Hepatocell Carcinoma. 10:181–191. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Singal AG, Yarchoan M, Yopp A, Sapisochin G, Pinato DJ and Pillai A: Neoadjuvant and adjuvant systemic therapy in HCC: Current status and the future. Hepatol Commun. 8:e04302024. View Article : Google Scholar : PubMed/NCBI | |
|
Elias D, Farace F, Triebel F, Hattchouel JM, Pignon JP, Lecesne A, Rougier P, Lasser P, Duvillard P and Escudier B: Phase I–II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectum. J Am Coll Surg. 181:303–310. 1995.PubMed/NCBI | |
|
Nakajima M, Hazama S, Tokumitsu Y, Shindo Y, Matsui H, Matsukuma S, Nakagami Y, Tamada K, Udaka K, Sakamoto M, et al: Phase I study of a novel therapeutic vaccine as perioperative treatment for patients with surgically resectable hepatocellular carcinoma: The YCP02 trial. Hepatol Res. 53:649–660. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Kaseb AO, Vence L, Blando J, Yadav SS, Ikoma N, Pestana RC, Vauthey JN, Allison JP and Sharma P: Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma. Cancer Immunol Res. 7:1390–1395. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Seckler F, Doussot A, Colpart P, Turco C, Calame P, Aubin F, Algros MP, Borg C, Nardin C and Heyd B: Preoperative immunotherapy for resectable hepatocellular carcinoma: Toward a paradigm shift? J Hepatol. 73:1588–1590. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liao H, Zhang Z, Chen J, Liao M, Xu L, Wu Z, Yuan K, Song B and Zeng Y: Preoperative radiomic approach to evaluate tumor-infiltrating CD8(+) T cells in hepatocellular carcinoma patients using contrast-enhanced computed tomography. Ann Surg Oncol. 26:4537–4547. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tian C, Yu Y, Wang Y, Yang L, Tang Y, Yu C, Feng G, Zheng D and Wang X: Neoadjuvant immune checkpoint inhibitors in hepatocellular carcinoma: A meta-analysis and systematic review. Front Immunol. 15:13528732024. View Article : Google Scholar : PubMed/NCBI | |
|
D'Alessio A, Stefanini B, Blanter J, Adegbite B, Crowley F, Yip V, Slater S, Fulgenzi CAM, Celsa C, Manfredi GF, et al: Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: A cross-trial, patient-level analysis. Lancet Oncol. 25:1465–1475. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Zhang Y, Zhang N, Ge Y and Jia W: Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: A case report. Onco Targets Ther. 12:7355–7359. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ho WJ, Sharma G, Zhu Q, Stein-O'Brien G, Durham J, Anders R, Popovic A, Mo G, Kamel I, Weiss M, et al: Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. J Immunother Cancer. 8:e0009322020. View Article : Google Scholar : PubMed/NCBI | |
|
Nakazawa M, Fang M, Vong T, Zorzi J, Griffith P, Anders RA, Oshima K, Kim AK, Laurin J, Lafaro KJ, et al: Impact of neoadjuvant immunotherapy on recurrence-free survival in patients with high-risk localized HCC. Cancer Res Commun. 4:2123–2132. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Han YH, Bo JQ and Liu LX: Neoadjuvant immunotherapy for resectable hepatocellular carcinoma: A systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 27:7134–7147. 2023.PubMed/NCBI | |
|
European Association for the Study of the Liver, . EASL clinical practice guidelines: Management of hepatocellular carcinoma. J Hepatol. 69:182–236. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, et al: Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. J Clin Oncol. 34:1510–1517. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Lencioni R, Montal R, Torres F, Park JW, Decaens T, Raoul JL, Kudo M, Chang C, Ríos J, Boige V, et al: Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. J Hepatol. 66:1166–1172. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Vernuccio F, Godfrey D, Meyer M, Williamson HV, Salama JK, Niedzwiecki D, Stephens SJ, Ronald J, Palta M and Marin D: Local tumor control and patient outcome using stereotactic body radiation therapy for hepatocellular carcinoma: iRECIST as a potential substitute for traditional criteria. AJR Am J Roentgenol. 213:1232–1239. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Cheung TT, Ho DWH, Lyu SX, Zhang Q, Tsui YM, Yu TC, Sze KM, Lee JM, Lau VW, Chu EY, et al: Multimodal integrative genomics and pathology analyses in neoadjuvant nivolumab treatment for intermediate and locally advanced hepatocellular carcinoma. Liver Cancer. 13:70–88. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Bruix J and Sherman M; American Association for the Study of Liver Diseases, : Management of hepatocellular carcinoma: An update. Hepatology. 53:1020–1022. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Gani RA, Teressa M, Budiman RA, Kalista KF and Lesmana CRA: Meta analysis of radiofrequency ablation versus surgical resection in small and large nodule of hepatocellular carcinoma. HPB (Oxford). 26:1216–1228. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Han JW and Yoon SK: Immune responses following locoregional treatment for hepatocellular carcinoma: Possible roles of adjuvant immunotherapy. Pharmaceutics. 13:13872021. View Article : Google Scholar : PubMed/NCBI | |
|
Xi M, Yang Z, Hu L, Fu Y, Hu D, Zhou Z, Liu M, Zhao J, Shen J, Li Q, et al: Radiofrequency ablation versus stereotactic body radiotherapy for recurrent small hepatocellular carcinoma: A randomized, open-label, controlled trial. J Clin Oncol. 43:1073–1082. 2025. View Article : Google Scholar : PubMed/NCBI | |
|
Campelo SN, Huang PH, Buie CR and Davalos RV: Recent advancements in electroporation technologies: From bench to clinic. Annu Rev Biomed Eng. 25:77–100. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Kumar P, Nagarajan A and Uchil PD: Electroporation. Cold Spring Harb Protoc. 2019.10.1101/pdb.top096271. 2019. View Article : Google Scholar | |
|
Tasu JP, Tougeron D and Rols MP: Irreversible electroporation and electrochemotherapy in oncology: State of the art. Diagn Interv Imaging. 103:499–509. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Bernelin-Cottet C, Urien C, McCaffrey J, Collins D, Donadei A, McDaid D, Jakob V, Barnier-Quer C, Collin N, Bouguyon E, et al: Electroporation of a nanoparticle-associated DNA vaccine induces higher inflammation and immunity compared to its delivery with microneedle patches in pigs. J Control Release. 308:14–28. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Rizzo A and Brandi G: Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun. 27:1003542021.PubMed/NCBI | |
|
Zhu SG, Li HB, Dai TX, Li H and Wang GY: Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: A case report. World J Clin Cases. 10:9743–9749. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Abudalou M, Vega EA, Kondratiev S, Conrad C and Kozyreva O: Complete pathological response to neoadjuvant chemoimmunotherapy in a patient with metastatic intrahepatic cholangiocarcinoma with high tumor mutational burden. Cureus. 13:e201872021.PubMed/NCBI | |
|
Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, Nam AR, Oh KS, Kim JM, Lee Y, et al: Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: An open-label, single-centre, phase 2 study. Lancet Gastroenterol Hepatol. 7:522–532. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W, Bie P, Liu L, Wen T, Kuang M, et al: Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 9:682–720. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Marie PK, Haymaker C, Parra ER, Kim YU, Lazcano R, Gite S, Lorenzini D, Wistuba II, Tidwell RSS, Song X, et al: Pilot clinical trial of perioperative durvalumab and tremelimumab in the treatment of resectable colorectal cancer liver metastases. Clin Cancer Res. 27:3039–3049. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang BC, Kuang BH, Lin GH and Fu C: Durvalumab and pembrolizumab in advanced biliary tract cancer: A reconstructed patient-level mimic head-to-head comparative analysis. Front Immunol. 15:14974152024. View Article : Google Scholar : PubMed/NCBI | |
|
Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, et al: Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies. Int J Cancer. 147:2190–2198. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Guidelines Working Committee of Chinese Society of Clinical Oncology, . Guideline of Chinese Society of Clinical Oncology (CSCO) Biliary Tract Cancer. People's Medical Publishing House. (Beijing, China). 2023.(In Chinese). | |
|
Shi GM, Huang XY, Wu D, Sun HC, Liang F, Ji Y, Chen Y, Yang GH, Lu JC, Meng XL, et al: Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-center, single-arm, phase 2 study. Signal Transduct Target Ther. 8:1062023. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Wu X, Wu H, Gu Y, Shao Y, Shao Q, Zhu F, Li X, Qian X, Hu J, et al: Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: A single-arm, open-label, phase II trial. J Immunother Cancer. 8:e0012402020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen X, Qin S, Gu S, Ren Z, Chen Z, Xiong J, Liu Y, Meng Z, Zhang X, Wang L, et al: Camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced biliary tract cancer: A multicenter, phase 2 trial. Int J Cancer. 149:1944–1954. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Klümpen HJ, Chan SL, Ozaka M, et al: Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 401:1853–1865. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, et al: Durvalumab plus Gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. 1:EVIDoa22000152022. View Article : Google Scholar : PubMed/NCBI | |
|
Pinter M, Scheiner B and Pinato DJ: Immune checkpoint inhibitors in hepatocellular carcinoma: Emerging challenges in clinical practice. Lancet Gastroenterol Hepatol. 8:760–770. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Mayoral M, Castañer E, Gallardo X, Andreu M, Dalmau E and Garcia Y: Tumor pseudoprogression during nivolumab immunotherapy for lung cancer. Radiología (Engl Ed). 61:498–505. 2019.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI | |
|
Billan S, Kaidar-Person O and Gil Z: Treatment after progression in the era of immunotherapy. Lancet Oncol. 21:e463–e476. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Peng X, Gong C, Zhang W and Zhou A: Advanced development of biomarkers for immunotherapy in hepatocellular carcinoma. Front Oncol. 12:10910882023. View Article : Google Scholar : PubMed/NCBI | |
|
Vignali DAA, Collison LW and Workman CJ: How regulatory T cells work. Nat Rev Immunol. 8:523–532. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wen J, Zhang X, Wong CC, Zhang Y, Pan Y, Zhou Y, Cheung AH, Liu Y, Ji F, Kang X, et al: Targeting squalene epoxidase restores anti-PD-1 efficacy in metabolic dysfunction-associated steatohepatitis-induced hepatocellular carcinoma. Gut. 73:2023–2036. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Goh CC, Roggerson KM, Lee HC, Golden-Mason L, Rosen HR and Hahn YS: Hepatitis C virus-induced myeloid-derived suppressor cells suppress NK cell IFN-γ production by altering cellular metabolism via arginase-1. J Immunol. 196:2283–2292. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Krüger C, Manns MP, Greten TF and Korangy F: A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4+CD25+Foxp3+ T cells. Gastroenterology. 135:234–243. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng JN, Yuan YX, Zhu B and Jia Q: Myeloid-derived suppressor cells: A Multifaceted accomplice in tumor progression. Front Cell Dev Biol. 9:7408272021. View Article : Google Scholar : PubMed/NCBI | |
|
Hudspeth K, Donadon M, Cimino M, Pontarini E, Tentorio P, Preti M, Hong M, Bertoletti A, Bicciato S, Invernizzi P, et al: Human liver-resident CD56bright/CD16neg NK cells are retained within hepatic sinusoids via the engagement of CCR5 and CXCR6 pathways. J Autoimmun. 66:40–50. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sanjabi S, Oh SA and Li MO: Regulation of the immune response by TGF-β: From conception to autoimmunity and infection. Cold Spring Harb Perspect Biol. 9:a0222362017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Zhang Y, Qin S, Zou B and Wang Y: Hepatitis B virus reactivation in cancer patients undergoing immune checkpoint inhibitors therapy: A systematic review. J Cancer. 13:3539–3553. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Burns EA, Muhsen I, Anand K, Xu J, Umoru G, Arain AN and Abdelrahim M: Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors. J Immunother. 44:132–139. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xia Z, Zhang J, Chen W, Zhou H, Du D, Zhu K, Chen H, Meng J and Yang J: Hepatitis B reactivation in cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis. Infect Dis Poverty. 12:872023. View Article : Google Scholar : PubMed/NCBI | |
|
Lee PC, Chao Y, Chen MH, Lan KH, Lee IC, Hou MC and Huang YH: Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 8:e0010722020. View Article : Google Scholar : PubMed/NCBI | |
|
Yibirin M, Mustafayev K, Hosry J, Pundhir P, Klingen J, Guevara EY, Granwehr BP, Kaseb A, Naing A, Patel S, et al: Immune checkpoint inhibitors suppress hepatitis C virus replication in infected patients with solid tumors. Am J Gastroenterol. 118:1609–1617. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Pinto E, Meneghel P, Farinati F, Russo FP, Pelizzaro F and Gambato M: Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role? Dig Liver Dis. 56:579–588. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Guo Z, Liu Y, Ling Q, Xu L, Wang T, Zhu J, Lin Y, Lu X, Qu W, Zhang F, et al: Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma: A multicenter, retrospective cohort study. Am J Transplant. 24:1837–1856. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Sedano R, Cabrera D, Jiménez A, Ma C, Jairath V, Arrese M and Arab JP: Immunotherapy for cancer: Common gastrointestinal, liver, and pancreatic side effects and their management. Am J Gastroenterol. 117:1917–1932. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
De Martin E, Michot JM, Papouin B, Champiat S, Mateus C, Lambotte O, Roche B, Antonini TM, Coilly A, Laghouati S, et al: Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 68:1181–1190. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Z, Zhu Y, Xie H and Zou Z: Immune-mediated hepatitis induced by immune checkpoint inhibitors: Current updates and future perspectives. Front Pharmacol. 13:10774682023. View Article : Google Scholar : PubMed/NCBI | |
|
Zen Y and Yeh MM: Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy. Semin Diagn Pathol. 36:434–440. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang N, Li Z, Liu Y, Shi X, Shi D, Li Y, Si X, Xun Z, Shao J, Zhao H and Wang H: Management and treatment of severe immune-related hepatotoxicity based on clinical and pathological characteristics. Hepatol Int. 18:1770–1780. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, et al: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: An open-label, single-arm phase II trial. Nat Med. 28:2155–2161. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Qin R, Jin T and Xu F: Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma. Front Immunol. 14:13260972023. View Article : Google Scholar : PubMed/NCBI |
